Report Summary
Eternity Insights can provide a deep dive research report highlighting the market and competitive in-telligence across the key segments of the market. The report also considers the impact of COVID-19 on the global Antidiabetics market. The report considers 2018-2020 historic period, 2021 as base year, and 2022-2028 as forecast period. The report includes quantitative analysis of the market supported by the mar-ket drivers, challenges, and trends to accurately map the market scenario and competition.
Antidiabetics market report is based on robust research methodology designed using blend of research ap-proaches developed using secondary/desk research and validated through the primary research and expert insights. Eternity Insights also uses paid data bases such as FACIVA, Hoovers, and other bench-marking and forecasting tools to provide accurate statistical analysis of supply and demand trends.
To learn more about this report
Key Research Highlights: Market Drivers
The Antidiabetics market is estimated to expand at a considerable growth rate during the forecast period ow-ing to increasing prevalence of venous diseases and increasing new product approvals to cater this demand. Rise in the awareness about the diseases, increasing importance of early diagnosis, and growing spending on chronic diseases are poised to boost the market growth. Moreover, the key players in the market are investing in research and development of technologically advanced products leading to increased utilization of the Antidiabetics products across developed and developing countries of the world.
Key Research Highlights: Market Restrains
Limited awareness about the diseases, high cost of products, low economical condition, and lack of favorable insurance systems restricts the adoption of Antidiabetics products across developing regions of the globe. However, launch of new products with low cost and increasing efforts for market penetration in these regions can offer lucrative growth opportunities for the players in the Antidiabetics market.
To learn more about this report
Key Research Highlights: Trends
Increasing research and development spending on Antidiabetics development has been the leading industry trend of Antidiabetics market
The leading players in the market are focused on developing products which are cost effective and high quality to tap the huge unaddressed opportunities in the developing regions. This can be wit-nessed from the increasing spending on research and development and growing number of new product approvals.
Global Antidiabetics Market Size, 2018-2028 (USD MILLION)
To learn more about this report
Market Segmentation
| Report Attributes |
Details |
| The market size value in 2021 |
USD XX.XX Million |
| CAGR (2021 - 2028) |
XX.XX % |
| The Revenue forecast in 2028 |
USD XX.XX Million |
| Base year for estimation |
2021 |
| Historical data |
2018-2019 |
| Forecast period |
2022-2028 |
| Quantitative units |
- Revenue in USD Million
- CAGR from 2021 to 2028
|
| Report coverage |
Revenue forecast, company ranking, competitive landscape, growth factors, and trends |
| Segments covered |
By Type Outlook, Application Outlook, Regional Outlook |
| By Type Outlook |
Type 1 Diabetes, Type 2 Diabetes, Other |
| By Application Outlook |
Hospital Use, Clinic Use, Household, Other |
| Regional scope |
North America, Europe, Asia Pacific, Latin America, Middle East & Africa |
| Country scope |
U.S., Canada, U.K., Germany, France, BENELUX, China, India, Japan, South Korea, Brazil, Saudi Arabia, UAE, Turkey |
| Key companies profiled |
Sanofi-Aventis, Takeda Pharmaceuticals, Eli Lilly, Oramed Pharmaceuticals, Boehringer Ingelheim, Merck & Co. Inc., Novo Nordisk, Bristol-Myers Squibb, Halozyme Therapeutics, Pfizer |
| Customization Available |
Yes, the report can be tailored to meet your specific requirements. |
Key Market Players
- Sanofi-Aventis
- Takeda Pharmaceuticals
- Eli Lilly
- Oramed Pharmaceuticals
- Boehringer Ingelheim
- Merck & Co. Inc.
- Novo Nordisk
- Bristol-Myers Squibb
- Halozyme Therapeutics
- Pfizer
Antidiabetics Market, By Type
- Type 1 Diabetes
- Type 2 Diabetes
- Other
Antidiabetics Market, By Application
- Hospital Use
- Clinic Use
- Household
- Other
Key Benefits To The Stake Holders
- Qualitative and quantitative analysis of the market based on segmentation involving both economic as well as non-economic factors
- Provision of market value (USD Billion) and volume (Tons) data for each segment and sub-segment
- Indicates the region and segment that is expected to witness the fastest growth as well as to dominate the market
- Analysis by geography highlighting the consumption of the product/service in the region as well as indicating the factors that are affecting the market within each region
- Competitive landscape which incorporates the market ranking of the major players, along with new service/product launches, partnerships, business expansions and acquisitions in the past five years of companies profiled
- Extensive company profiles comprising of company overview, company insights, product benchmarking and SWOT analysis for the major market players
- The current as well as the future market outlook of the industry with respect to recent developments (which involve growth opportunities and drivers as well as challenges and restraints of both emerging as well as developed regions
Table Of Contents
Table of Contents
1 Study Coverage
1.1 Antidiabetics Product
1.2 Market Segments
1.3 Key Manufacturers Covered
1.4 Market by Type
1.4.1 Global Antidiabetics Market Size Growth Rate by Product
1.4.2 Type 1 Diabetes
1.4.3 Type 2 Diabetes
1.4.4 Other
1.5 Market by End User
1.5.1 Global Antidiabetics Market Size Growth Rate by End User
1.5.2 Hospital Use
1.5.3 Clinic Use
1.5.4 Household
1.5.5 Other
1.6 Study Objectives
1.7 Years Considered
2 Executive Summary
2.1 Global Antidiabetics Market Size
2.1.1 Global Antidiabetics Revenue 2017-2027
2.1.2 Global Antidiabetics Sales 2017-2027
2.2 Antidiabetics Growth Rate by Regions
2.2.1 Global Antidiabetics Sales by Regions
2.2.2 Global Antidiabetics Revenue by Regions
3 Breakdown Data by Manufacturers
3.1 Antidiabetics Sales by Manufacturers
3.1.1 Antidiabetics Sales by Manufacturers
3.1.2 Antidiabetics Sales Market Share by Manufacturers
3.1.3 Global Antidiabetics Market Concentration Ratio (CR5 and HHI)
3.2 Antidiabetics Revenue by Manufacturers
3.2.1 Antidiabetics Revenue by Manufacturers (2017-2020)
3.2.2 Antidiabetics Revenue Share by Manufacturers (2017-2020)
3.3 Antidiabetics Price by Manufacturers
3.4 Antidiabetics Manufacturing Base Distribution, Product Types
3.4.1 Antidiabetics Manufacturers Manufacturing Base Distribution, Headquarters
3.4.2 Manufacturers Antidiabetics Product Type
3.4.3 Date of International Manufacturers Enter into Antidiabetics Market
3.5 Manufacturers Mergers & Acquisitions, Expansion Plans
4 Breakdown Data by Product
4.1 Global Antidiabetics Sales by Product
4.2 Global Antidiabetics Revenue by Product
4.3 Antidiabetics Price by Product
5 Breakdown Data by End User
5.1 Overview
5.2 Global Antidiabetics Breakdown Data by End User
6 North America
6.1 North America Antidiabetics by Countries
6.1.1 North America Antidiabetics Sales by Countries
6.1.2 North America Antidiabetics Revenue by Countries
6.1.3 United States
6.1.4 Canada
6.1.5 Mexico
6.2 North America Antidiabetics by Product
6.3 North America Antidiabetics by End User
7 Europe
7.1 Europe Antidiabetics by Countries
7.1.1 Europe Antidiabetics Sales by Countries
7.1.2 Europe Antidiabetics Revenue by Countries
7.1.3 Germany
7.1.4 France
7.1.5 UK
7.1.6 Italy
7.1.7 Russia
7.2 Europe Antidiabetics by Product
7.3 Europe Antidiabetics by End User
8 Asia Pacific
8.1 Asia Pacific Antidiabetics by Countries
8.1.1 Asia Pacific Antidiabetics Sales by Countries
8.1.2 Asia Pacific Antidiabetics Revenue by Countries
8.1.3 China
8.1.4 Japan
8.1.5 Korea
8.1.6 India
8.1.7 Australia
8.1.8 Indonesia
8.1.9 Malaysia
8.1.10 Philippines
8.1.11 Thailand
8.1.12 Vietnam
8.1.13 Singapore
8.2 Asia Pacific Antidiabetics by Product
8.3 Asia Pacific Antidiabetics by End User
9 Central & South America
9.1 Central & South America Antidiabetics by Countries
9.1.1 Central & South America Antidiabetics Sales by Countries
9.1.2 Central & South America Antidiabetics Revenue by Countries
9.1.3 Brazil
9.2 Central & South America Antidiabetics by Product
9.3 Central & South America Antidiabetics by End User
10 Middle East and Africa
10.1 Middle East and Africa Antidiabetics by Countries
10.1.1 Middle East and Africa Antidiabetics Sales by Countries
10.1.2 Middle East and Africa Antidiabetics Revenue by Countries
10.1.3 GCC Countries
10.1.4 Turkey
10.1.5 Egypt
10.1.6 South Africa
10.2 Middle East and Africa Antidiabetics by Product
10.3 Middle East and Africa Antidiabetics by End User
11 Company Profiles
11.1 Sanofi-Aventis
11.1.1 Sanofi-Aventis Company Details
11.1.2 Company Business Overview
11.1.3 Sanofi-Aventis Antidiabetics Sales, Revenue and Gross Margin (2017-2020)
11.1.4 Sanofi-Aventis Antidiabetics Products Offered
11.1.5 Sanofi-Aventis Recent Development
11.2 Takeda Pharmaceuticals
11.2.1 Takeda Pharmaceuticals Company Details
11.2.2 Company Business Overview
11.2.3 Takeda Pharmaceuticals Antidiabetics Sales, Revenue and Gross Margin (2017-2020)
11.2.4 Takeda Pharmaceuticals Antidiabetics Products Offered
11.2.5 Takeda Pharmaceuticals Recent Development
11.3 Eli Lilly
11.3.1 Eli Lilly Company Details
11.3.2 Company Business Overview
11.3.3 Eli Lilly Antidiabetics Sales, Revenue and Gross Margin (2017-2020)
11.3.4 Eli Lilly Antidiabetics Products Offered
11.3.5 Eli Lilly Recent Development
11.4 Oramed Pharmaceuticals
11.4.1 Oramed Pharmaceuticals Company Details
11.4.2 Company Business Overview
11.4.3 Oramed Pharmaceuticals Antidiabetics Sales, Revenue and Gross Margin (2017-2020)
11.4.4 Oramed Pharmaceuticals Antidiabetics Products Offered
11.4.5 Oramed Pharmaceuticals Recent Development
11.5 Boehringer Ingelheim
11.5.1 Boehringer Ingelheim Company Details
11.5.2 Company Business Overview
11.5.3 Boehringer Ingelheim Antidiabetics Sales, Revenue and Gross Margin (2017-2020)
11.5.4 Boehringer Ingelheim Antidiabetics Products Offered
11.5.5 Boehringer Ingelheim Recent Development
11.6 Merck & Co. Inc.
11.6.1 Merck & Co. Inc. Company Details
11.6.2 Company Business Overview
11.6.3 Merck & Co. Inc. Antidiabetics Sales, Revenue and Gross Margin (2017-2020)
11.6.4 Merck & Co. Inc. Antidiabetics Products Offered
11.6.5 Merck & Co. Inc. Recent Development
11.7 Novo Nordisk
11.7.1 Novo Nordisk Company Details
11.7.2 Company Business Overview
11.7.3 Novo Nordisk Antidiabetics Sales, Revenue and Gross Margin (2017-2020)
11.7.4 Novo Nordisk Antidiabetics Products Offered
11.7.5 Novo Nordisk Recent Development
11.8 Bristol-Myers Squibb
11.8.1 Bristol-Myers Squibb Company Details
11.8.2 Company Business Overview
11.8.3 Bristol-Myers Squibb Antidiabetics Sales, Revenue and Gross Margin (2017-2020)
11.8.4 Bristol-Myers Squibb Antidiabetics Products Offered
11.8.5 Bristol-Myers Squibb Recent Development
11.9 Halozyme Therapeutics
11.9.1 Halozyme Therapeutics Company Details
11.9.2 Company Business Overview
11.9.3 Halozyme Therapeutics Antidiabetics Sales, Revenue and Gross Margin (2017-2020)
11.9.4 Halozyme Therapeutics Antidiabetics Products Offered
11.9.5 Halozyme Therapeutics Recent Development
11.10 Pfizer
11.10.1 Pfizer Company Details
11.10.2 Company Business Overview
11.10.3 Pfizer Antidiabetics Sales, Revenue and Gross Margin (2017-2020)
11.10.4 Pfizer Antidiabetics Products Offered
11.10.5 Pfizer Recent Development
12 Future Forecast
12.1 Antidiabetics Market Forecast by Regions
12.1.1 Global Antidiabetics Sales Forecast by Regions 2021-2027
12.1.2 Global Antidiabetics Revenue Forecast by Regions 2021-2027
12.2 Antidiabetics Market Forecast by Product
12.2.1 Global Antidiabetics Sales Forecast by Product 2021-2027
12.2.2 Global Antidiabetics Revenue Forecast by Product 2021-2027
12.3 Antidiabetics Market Forecast by End User
12.4 North America Antidiabetics Forecast
12.5 Europe Antidiabetics Forecast
12.6 Asia Pacific Antidiabetics Forecast
12.7 Central & South America Antidiabetics Forecast
12.8 Middle East and Africa Antidiabetics Forecast
13 Market Opportunities, Challenges, Risks and Influences Factors Analysis
13.1 Market Opportunities and Drivers
13.2 Market Challenges
13.3 Market Risks/Restraints
13.4 Macroscopic Indicators
14 Value Chain and Sales Channels Analysis
14.1 Value Chain Analysis
14.2 Antidiabetics Customers
14.3 Sales Channels Analysis
14.3.1 Sales Channels
14.3.2 Distributors
15 Research Findings and Conclusion
16 Appendix
16.1 Research Methodology
16.1.1 Methodology/Research Approach
16.1.2 Data Source
16.2 Author Details
16.3 Disclaimer
